We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen Presents Positive Data From Rituxan Biosimilar Study
Read MoreHide Full Article
Amgen Inc (AMGN - Free Report) and partner Allergan’s comparative clinical study evaluating ABP 798, their biosimilar candidate, to Roche’s (RHHBY - Free Report) Rituxan showed clinical equivalence of the biosimilar product to the branded version. The study evaluated efficacy and safety of ABP 798 compared to Rituxan in patients with non-Hodgkin's lymphoma (NHL).
Top-line data from the JASMINE study showed that the primary endpoint, an assessment of overall response rate (ORR) by week 28, was within the pre-specified margin for ABP 798 compared to Rituxan. This is the second study on ABP 798 that has shown positive top-line results.
In January, Amgen and Allergan announced positive top-line results from phase I/III study of ABP 798, evaluating pharmacokinetics, efficacy and safety of ABP 798 compared to Rituxan in patients with moderate-to-severe rheumatoid arthritis. The study met its primary endpoint of pharmacokinetic (PK) similarity. The study also established equivalent efficacy and demonstrated a similar safety profile to Rituxan.
Shares of Amgen have risen 4.5% this year so far against a 1.2% decrease registered by the industry during this period.
Amgen has a total of 10 biosimilars in its portfolio. It has collaborated with Allergan for the worldwide development and commercialization of four oncology antibody biosimilar medicines including Rituxan. Last month, Amgen and Allergan launched Mvasi and Kanjinti, biosimilar versions of Roche’s blockbuster medicines, Avastin and Herceptin, respectively in the United States. While Kanjinti is marketed in EU as well, Mvasi is approved in EU but not yet launched.
Meanwhile, Amgen has been marketing Amgevita (biosimilar of AbbVie’s [(ABBV - Free Report) ] Humira) in the EU since October last year. Amjevita (trade name of Humira biosimilar in the United States), though approved in the country, is expected to be launched in 2023 per a settlement with AbbVie. A biosimilar version of Johnson and Johnson/Merck’s Remicade (ABP 710) is also under review in the United States (FDA decision expected in December) and EU while a biosimilar of Alexion’s Soliris (ABP 959) is in late state development.
Amgen expects to launch additional biosimilars in the second half/2020 across multiple geographies. Amgen has also tied up with Daiichi Sankyo for the commercialization of some biosimilars in Japan.
In 2019 so far, biosimilars have generated revenues of $137 million for Amgen, all from international markets, With Mvasi and Kanjinti launched in the United States, biosimilars revenues should be higher in the second half. Biosimilars could be an important long-term growth driver for the company, especially as its mature drugs like Enbrel, Aranesp, Epogen, Neupogen and Neulasta are facing an array of branded and biosimilar competitors.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Amgen Presents Positive Data From Rituxan Biosimilar Study
Amgen Inc (AMGN - Free Report) and partner Allergan’s comparative clinical study evaluating ABP 798, their biosimilar candidate, to Roche’s (RHHBY - Free Report) Rituxan showed clinical equivalence of the biosimilar product to the branded version. The study evaluated efficacy and safety of ABP 798 compared to Rituxan in patients with non-Hodgkin's lymphoma (NHL).
Top-line data from the JASMINE study showed that the primary endpoint, an assessment of overall response rate (ORR) by week 28, was within the pre-specified margin for ABP 798 compared to Rituxan. This is the second study on ABP 798 that has shown positive top-line results.
In January, Amgen and Allergan announced positive top-line results from phase I/III study of ABP 798, evaluating pharmacokinetics, efficacy and safety of ABP 798 compared to Rituxan in patients with moderate-to-severe rheumatoid arthritis. The study met its primary endpoint of pharmacokinetic (PK) similarity. The study also established equivalent efficacy and demonstrated a similar safety profile to Rituxan.
Shares of Amgen have risen 4.5% this year so far against a 1.2% decrease registered by the industry during this period.
Amgen has a total of 10 biosimilars in its portfolio. It has collaborated with Allergan for the worldwide development and commercialization of four oncology antibody biosimilar medicines including Rituxan. Last month, Amgen and Allergan launched Mvasi and Kanjinti, biosimilar versions of Roche’s blockbuster medicines, Avastin and Herceptin, respectively in the United States. While Kanjinti is marketed in EU as well, Mvasi is approved in EU but not yet launched.
Meanwhile, Amgen has been marketing Amgevita (biosimilar of AbbVie’s [(ABBV - Free Report) ] Humira) in the EU since October last year. Amjevita (trade name of Humira biosimilar in the United States), though approved in the country, is expected to be launched in 2023 per a settlement with AbbVie. A biosimilar version of Johnson and Johnson/Merck’s Remicade (ABP 710) is also under review in the United States (FDA decision expected in December) and EU while a biosimilar of Alexion’s Soliris (ABP 959) is in late state development.
Amgen expects to launch additional biosimilars in the second half/2020 across multiple geographies. Amgen has also tied up with Daiichi Sankyo for the commercialization of some biosimilars in Japan.
In 2019 so far, biosimilars have generated revenues of $137 million for Amgen, all from international markets, With Mvasi and Kanjinti launched in the United States, biosimilars revenues should be higher in the second half. Biosimilars could be an important long-term growth driver for the company, especially as its mature drugs like Enbrel, Aranesp, Epogen, Neupogen and Neulasta are facing an array of branded and biosimilar competitors.
Amgen currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>